FDA approves Daraxonrasib this year?

Daraxonrasib is an RAS inhibitor drug developed by Revolution Medicines and currently in trial to treat RAS-mutated cancers. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional appr…